This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
by Zacks Equity Research
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
FOLDPositive Net Change ANIPNegative Net Change CRMDPositive Net Change VTRSNegative Net Change
biotechnology medical pharmaceuticals
Cencora to Acquire OneOncology to Expand Community Oncology Solutions
by Zacks Equity Research
COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.
MDPositive Net Change CORPositive Net Change BDSXNegative Net Change BTSGPositive Net Change
medical medical-devices
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
by Zacks Equity Research
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
BSXNegative Net Change ISRGPositive Net Change MEDPPositive Net Change PLSEPositive Net Change
medical medical-devices
4 Outpatient Home Health Stocks in Focus as Market Dynamics Change
by Zacks Equity Research
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.
DVANegative Net Change EHCNegative Net Change PNTGNegative Net Change OPCHPositive Net Change
medical medical-devices
National Vision Stock Surges 154.6% in a Year: What's Driving it?
by Zacks Equity Research
EYE shares jump 154% in a year as America's Best fuels comps, new stores and fleet optimization, showing early gains from strategic execution.
ILMNPositive Net Change PODDNegative Net Change EYEPositive Net Change BTSGPositive Net Change
medical medical-devices
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
by Zacks Equity Research
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
NVOPositive Net Change LLYPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Initiates Coverage of CPIX With Outperform Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Cumberland as "Outperform." Explore how CPIX's scalable commercial model, long-duration Talicia revenues and pipeline upside create an attractive risk-reward setup for investors.
CPIXPositive Net Change
medical
3 MedTech Innovators Shaping Healthcare in 2026: AVAH, INGN & CCLD
by Indrajit Bandyopadhyay
AVAH, INGN & CCLD show how home care, portable oxygen tech and cloud healthcare IT are reshaping care delivery and efficiency into 2026.
INGNNegative Net Change AVAHPositive Net Change CCLDNegative Net Change
medical medical-devices
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
by Zacks Equity Research
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.
MEDPPositive Net Change KRMDPositive Net Change CCLDNegative Net Change RVTYNegative Net Change
medical medical-devices
Is the Options Market Predicting a Spike in TG Therapeutics Stock?
by Zacks Equity Research
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TGTXPositive Net Change
medical
Trump Orders Marijuana Reclassification: What It Means for the Sector
by Sundeep Ganoria
Trump's executive order to move marijuana to Schedule III could reshape cannabis regulation and taxes, lifting sentiment around cannabis stocks.
CGCNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
by Ekta Bagri
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Tempus AI Approaching Profitability Despite GAAP Losses
by Sridatri Sarkar
TEM shows early profitability inflection with first positive Adjusted EBITDA in Q3 2025, raised revenue guidance and disciplined spending despite GAAP losses.
GDRXPositive Net Change HIMSPositive Net Change TEMPositive Net Change
medical
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNPositive Net Change JNJNegative Net Change HALOPositive Net Change
biotechs medical pharmaceuticals
Universal Health at 9.6X Earnings: A Rare Discount in Hospital Stocks?
by Kaibalya Pravo Dey
UHS trades at just 9.6X forward earnings, below peers and its own history, as steady volume growth, rising margins and strong cash flows lift investor appeal.
UHSPositive Net Change THCPositive Net Change HCAPositive Net Change
medical
ECL Boosts High-Tech Water Platform With Ovivo's Electronics Business
by Zacks Equity Research
Ecolab closes Ovivo Electronics acquisition, expanding high-tech water solutions for semiconductors and boosting circular water offerings.
BSXNegative Net Change ECLPositive Net Change ISRGPositive Net Change MEDPPositive Net Change
medical medical-devices
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
by Zacks Equity Research
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs medical
Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?
by Zacks Equity Research
DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.
LHNegative Net Change DHRNegative Net Change CVSNegative Net Change
medical
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
by Ahan Chakraborty
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
by Zacks Equity Research
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
NVSPositive Net Change QGENPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
by Zacks Equity Research
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
RHHBYPositive Net Change CRMDPositive Net Change PCSANegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
by Zacks Equity Research
Here are some surging MedTech stocks - GMED, TMDX and HIMS - that may face slowing momentum in 2026.
GMEDPositive Net Change TMDXPositive Net Change HIMSPositive Net Change
medical medical-devices
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
by Zacks Equity Research
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.
BSXNegative Net Change ISRGPositive Net Change DVANegative Net Change MEDPPositive Net Change
medical medical-devices
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
by Zacks Equity Research
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
ILMNPositive Net Change CRLPositive Net Change PODDNegative Net Change BTSGPositive Net Change
medical medical-devices
Will Direct Distribution in Southern Europe Boost ISRG's Margins?
by Indrajit Bandyopadhyay
ISRG plans a 2026 shift to direct distribution in Italy, Spain, and Portugal, aiming to lift margins by capturing distributor economics with execution risk.
SYKPositive Net Change ISRGPositive Net Change ZBHNegative Net Change
medical medical-devices